151 related articles for article (PubMed ID: 19950316)
21. Interlukin-6 receptor inhibitor tocilizumab: a new treatment option in rheumatoid arthritis?
Johnson J; Wang MY
Neurosurgery; 2008 Aug; 63(2):N8. PubMed ID: 18797345
[No Abstract] [Full Text] [Related]
22. Switching to the anti-interleukin-6 receptor antibody tocilizumab in rheumatoid arthritis patients refractory to antitumor necrosis factor biologics.
Kawashiri SY; Kawakami A; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Arima K; Ichinose K; Kamachi M; Yamasaki S; Nakamura H; Origuchi T; Ida H; Eguchi K
Mod Rheumatol; 2010 Feb; 20(1):40-5. PubMed ID: 19802651
[TBL] [Abstract][Full Text] [Related]
23. Radiographic improvement of damaged large joints in children with systemic juvenile idiopathic arthritis following tocilizumab treatment.
Inaba Y; Ozawa R; Imagawa T; Mori M; Hara Y; Miyamae T; Aoki C; Saito T; Yokota S
Ann Rheum Dis; 2011 Sep; 70(9):1693-5. PubMed ID: 21402562
[No Abstract] [Full Text] [Related]
24. [Biological agents for therapy of rheumatoid arthritis--overview].
Takeuchi T
Nihon Rinsho; 2005 Jan; 63 Suppl 1():513-6. PubMed ID: 15799409
[No Abstract] [Full Text] [Related]
25. [Treatment of reactive arthritis with infliximab].
Abdelmoula LC; Yahia CB; Testouri N; Tekaya R; Ben M'barek R; Chaabouni L; Zouari R
Tunis Med; 2008 Dec; 86(12):1095-7. PubMed ID: 19213526
[No Abstract] [Full Text] [Related]
26. Treatment of reactive arthritis with biological agents: a review.
Zeng H; Luo B; Zhang Y; Xie Z; Ye Z
Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32039436
[TBL] [Abstract][Full Text] [Related]
27. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab.
Shima Y; Kuwahara Y; Murota H; Kitaba S; Kawai M; Hirano T; Arimitsu J; Narazaki M; Hagihara K; Ogata A; Katayama I; Kawase I; Kishimoto T; Tanaka T
Rheumatology (Oxford); 2010 Dec; 49(12):2408-12. PubMed ID: 20819796
[TBL] [Abstract][Full Text] [Related]
28. Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibody.
Ogawa J; Harigai M; Akashi T; Nagasaka K; Suzuki F; Tominaga S; Miyasaka N
Ann Rheum Dis; 2006 Dec; 65(12):1667-9. PubMed ID: 17105857
[No Abstract] [Full Text] [Related]
29. Effectiveness and safety of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in a patient with refractory GI graft-versus-host disease.
Gergis U; Arnason J; Yantiss R; Shore T; Wissa U; Feldman E; Woodworth T
J Clin Oncol; 2010 Oct; 28(30):e602-4. PubMed ID: 20713858
[No Abstract] [Full Text] [Related]
30. Immediate reduction of white blood cell count after tocilizumab administration was observed in some cases.
Nagamine R; Chen W; Hara T; Kondo K; Sugioka Y
Mod Rheumatol; 2009; 19(3):348-50. PubMed ID: 19288171
[No Abstract] [Full Text] [Related]
31. Tocilizumab for rheumatoid arthritis.
Drug Ther Bull; 2010 Jan; 48(1):9-12. PubMed ID: 20040568
[TBL] [Abstract][Full Text] [Related]
32. Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody.
Nishimoto N; Nakahara H; Yoshio-Hoshino N; Mima T
Arthritis Rheum; 2008 Apr; 58(4):1197-200. PubMed ID: 18383395
[TBL] [Abstract][Full Text] [Related]
33. Tocilizumab and mesenteric arterial thrombosis: drug-drug interaction with anticoagulants metabolized by CYP 450 and/or by P-glycoprotein.
Clarivet B; Robin P; Pers YM; Ferreira R; Lebrun J; Jorgensen C; Hillaire-Buys D; Brés V; Faillie JL
Eur J Clin Pharmacol; 2016 Nov; 72(11):1413-1414. PubMed ID: 27457374
[No Abstract] [Full Text] [Related]
34. Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors.
Genovese MC; Fleischmann RM; Greenwald M; Satterwhite J; Veenhuizen M; Xie L; Berclaz PY; Myers S; Benichou O
Ann Rheum Dis; 2013 Sep; 72(9):1461-8. PubMed ID: 23268367
[TBL] [Abstract][Full Text] [Related]
35. Clinical characteristics of influenza virus infection in juvenile idiopathic arthritis patients treated with tocilizumab.
Kawada J; Kitagawa Y; Iwata N; Ito Y
Mod Rheumatol; 2013 Sep; 23(5):972-6. PubMed ID: 23070362
[TBL] [Abstract][Full Text] [Related]
36. Arthralgia as an adverse event to infliximab: a reactive arthritis or triggering of psoriatic arthritis? Successful management by switching to etanercept.
Moustou AE; Stratigos AJ; Vergou T; Gregoriou S; Georgala S; Danopoulou I
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):968-9. PubMed ID: 19207660
[No Abstract] [Full Text] [Related]
37. A clinical perspective of rheumatoid arthritis.
Scherer HU; Burmester GR
Eur J Immunol; 2009 Aug; 39(8):2044-8. PubMed ID: 19672900
[TBL] [Abstract][Full Text] [Related]
38. Tocilizumab for rheumatoid and juvenile idiopathic arthritis.
Bongartz T
Lancet; 2008 Mar; 371(9617):961-3. PubMed ID: 18358909
[No Abstract] [Full Text] [Related]
39. [Humanized anti-human IL-6 receptor antibody, tocilizumab].
Nishimoto N
Nihon Rinsho; 2007 Jul; 65(7):1218-25. PubMed ID: 17642235
[TBL] [Abstract][Full Text] [Related]
40. Sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in two patients with refractory relapsing polychondritis.
Kawai M; Hagihara K; Hirano T; Shima Y; Kuwahara Y; Arimitsu J; Narazaki M; Ogata A; Kawase I; Kishimoto T; Tanaka T
Rheumatology (Oxford); 2009 Mar; 48(3):318-9. PubMed ID: 19106169
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
